FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the week’s most important news in pharma and biotech including imminent US approval of Johnson & Johnson’s one-shot COVID-19 vaccine, encouraging real world evidence for Pfizer and AstraZeneca’s vaccines, Moderna gearing up to tackle virus variants, the future for JAK inhibitors and Merck & Co.’s acquisition of Pandion Therapeutics.